Valproic Acid/Barbiturates; Hydantoins
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
When these two medicines are taken together, your body may not process your barbiturate or valproic acid properly.
What might happen:
Your blood levels of barbiturate may increase and cause toxic effects. Your blood levels of valproic acid could decrease, reducing the beneficial effects of this medicine.
What you should do about this interaction:
Let your healthcare professional (e.g. doctor or pharmacist) know that you are taking these medicines together. If you experience drowsiness, headache, dizziness, slowed/difficult breathing, confusion, nausea, vomiting or decreased effectiveness of valproic acid (e.g. increase in seizures, migraine headaches, or unstable mood) contact your doctor. Your doctor may check medicine blood levels and may need to adjust the dose of one or both medicines.Your healthcare professionals (e.g. doctor or pharmacist) may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Depakote (divalproex sodium) US prescribing information. AbbVie Inc. June, 2013.
2.Patel IH, Levy RH, Cutler RE. Phenobarbital--valproic acid interaction. Clin Pharmacol Ther 1980 Apr;27(4):515-21.
3.Bruni J, Wilder BJ, Perchalski RJ, Hammond EJ, Villarreal HJ. Valproic acid and plasma levels of phenobarbital. Neurology 1980 Jan;30(1):94-7.
4.Windorfer A Jr, Sauer W, Gadeke R. Elevation of diphenylhydantoin and primidone serum concentration by addition of dipropylacetate, a new anticonvulsant drug. Acta Paediatr Scand 1975 Sep;64(5):771-2.
5.Bardy A, Hari R, Lehtovaara R, Majuri H. Valproate may lower serum-phenytoin. Lancet 1976 Dec 11;2(7998):1297-8.
6.Patsalos PN, Lascelles PT. Valproate may lower serum-phenytoin. Lancet 1977 Jan 1;1(8001):50-1.
7.Patsalos PN, Lascelles PT. Effect of sodium valproate on plasma protein binding of diphenylhydantoin. J Neurol Neurosurg Psychiatry 1977 Jun; 40(6):570-4.
8.Wilder BJ, Willmore LJ, Bruni J, Villarreal HJ. Valproic acid: interaction with other anticonvulsant drugs. Neurology 1978 Sep;28(9 Pt 1):892-6.
9.Dahlqvist R, Borga O, Rane A, Walsh Z, Sjoqvist F. Decreased plasma protein binding of phenytoin in patients on valproic acid. Br J Clin Pharmacol 1979 Dec;8(6):547-52.
10.Reunanen MI, Luoma P, Myllyla VV, Hokkanen E. Low serum valproic acid concentrations in epileptic patients on combination therapy. Curr Ther Res 1980 Sep;28(3):456-62.
11.Sansom LN, Beran RC, Schapel GJ. Interaction between phenytoin and valproate. Med J Aust 1980 Aug 23;2(4):212.
12.Monks A, Richens A. Effect of single doses of sodium valproate on serum phenytoin levels and protein binding in epileptic patients. Clin Pharmacol Ther 1980 Jan;27(1):89-95.
13.Bruni J, Gallo JM, Lee CS, Perchalski RJ, Wilder BJ. Interactions of valproic acid with phenytoin. Neurology 1980 Nov;30(11):1233-6.
14.Henriksen O, Johannessen SI. Clinical and pharmacokinetic observations on sodium valproate - a 5- year follow-up study in 100 children with epilepsy. Acta Neurol Scand 1982 May;65(5):504-23.
15.Palm R, Silseth C, Alvan G. Phenytoin intoxication as the first symptom of fatal liver damage induced by sodium valproate. Br J Clin Pharmacol 1984 May;17(5):597-9.
16.Riva R, Albani F, Contin M, Perucca E, Ambrosetto G, Gobbi G, Santucci M, Procaccianti G, Baruzzi A. Time-dependent interaction between phenytoin and valproic acid. Neurology 1985 Apr;35(4):510-5.
17.Miles MV, Snead OC 3rd, Thorn MD. Predictability of unbound antiepileptic drug concentrations in children treated with valproic acid and phenytoin. Clin Pharm 1988 Sep;7(9):688-93.
18.Haidukewych D, Rodin EA, Zielinski JJ. Derivation and evaluation of an equation for prediction of free phenytoin concentration in patients co-medicated with valproic acid. Ther Drug Monit 1989;11(2):134-9.
19.Johnson GJ, Kilpatrick CJ, Bury RW, Fullinfaw RO, Moulds RF. Unbound phenytoin plasma concentrations in patients comedicated with sodium valproate--the predictive value of plasma albumin concentration. Br J Clin Pharmacol 1989 Jun;27(6):843-9.
20.May T, Rambeck B. Fluctuations of unbound and total phenytoin concentrations during the day in epileptic patients on valproic acid comedication. Ther Drug Monit 1990 Mar;12(2):124-8.